These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 15479218)

  • 1. Role of early insulin secretion in postglucose-loading hyperglycaemia and postfat-loading hyperlipidaemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats.
    Mori Y; Kitahara Y; Miura K; Mine T; Tajima N
    Diabetes Obes Metab; 2004 Nov; 6(6):422-31. PubMed ID: 15479218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats.
    Mori Y; Ojima K; Fuujimori Y; Aoyagi I; Kusama H; Yamazaki Y; Kojima M; Shibata N; Itoh Y; Tajima N
    Endocrine; 2006 Apr; 29(2):309-15. PubMed ID: 16785606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading.
    Mori Y; Kitahara Y; Miura K; Tajima N
    Endocrine; 2004 Feb; 23(1):39-43. PubMed ID: 15034195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
    Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
    Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide.
    Mine T; Miura K; Kitahara Y; Okano A; Kawamori R
    Biol Pharm Bull; 2002 Nov; 25(11):1412-6. PubMed ID: 12419950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.
    Mori Y; Itoh Y; Obata T; Tajima N
    Endocrine; 2006 Feb; 29(1):143-8. PubMed ID: 16622303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats.
    Iwase M; Nakamura U; Uchizono Y; Nohara S; Sasaki N; Sonoki K; Iida M
    Eur J Pharmacol; 2005 Aug; 518(2-3):243-50. PubMed ID: 16023099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
    Tuomi T; Honkanen EH; Isomaa B; Sarelin L; Groop LC
    Diabetes Care; 2006 Feb; 29(2):189-94. PubMed ID: 16443858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes assessment by meal tolerance test.
    Mori Y; Kuriyama G; Tajima N
    Endocrine; 2004 Dec; 25(3):203-6. PubMed ID: 15758246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nateglinide prevents fatty liver through up-regulation of lipid oxidation pathway in Goto-Kakizaki rats on a high-fat diet.
    Mine T; Miura K; Kajioka T; Kitahara Y
    Metabolism; 2008 Jan; 57(1):140-8. PubMed ID: 18078871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight loss-associated changes in acute effects of nateglinide on insulin secretion after glucose loading: results of glucose loading on 2 consecutive days.
    Mori Y; Mamori S; Tajima N
    Diabetes Obes Metab; 2005 Mar; 7(2):182-8. PubMed ID: 15715891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion.
    Uto Y; Teno S; Iwamoto Y; Omori Y; Takizawa T
    Metabolism; 2002 Jan; 51(1):20-4. PubMed ID: 11782867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
    Kikuchi M
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide.
    Ikenoue T; Okazaki K; Fujitani S; Tsuchiya Y; Akiyoshi M; Maki T; Kondo N
    Biol Pharm Bull; 1997 Apr; 20(4):354-9. PubMed ID: 9145209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics, insulinotropic action and hypoglycemic effect of nateglinide and glibenclamide in normal and diabetic rats.
    Courtois P; Jijakli H; Ladriere L; Oguzhan B; Sener A; Malaisse WJ
    Int J Mol Med; 2003 Jan; 11(1):105-9. PubMed ID: 12469228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.
    Kahn SE; Montgomery B; Howell W; Ligueros-Saylan M; Hsu CH; Devineni D; McLeod JF; Horowitz A; Foley JE
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5824-9. PubMed ID: 11739446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of early insulin secretion after a meal in type 2 diabetes: effects on lipid and glucose metabolism.
    Dimitriadis G; Boutati E; Lambadiari V; Mitrou P; Maratou E; Brunel P; Raptis SA
    Eur J Clin Invest; 2004 Jul; 34(7):490-7. PubMed ID: 15255786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.
    Voytovich MH; Haukereid C; Hjelmesaeth J; Hartmann A; Løvik A; Jenssen T
    Clin Transplant; 2007; 21(2):246-51. PubMed ID: 17425753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes.
    Johanson EH; Jansson PA; Gustafson B; Sandqvist M; Taskinen MR; Smith U; Axelsen M
    Diabetes Metab Res Rev; 2005; 21(4):376-81. PubMed ID: 15724236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of glibenclamide and nateglinide upon pancreatic islet function in normal and diabetic rats.
    Laghmich A; Ladrière L; Malaisse-Lagae F; Malaisse WJ
    Pharmacol Res; 1999 Dec; 40(6):475-82. PubMed ID: 10660944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.